Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer,Kidney International

当前位置： X-MOL 学术 › Kidney Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
Kidney International ( IF 14.8 ) Pub Date : 2022-08-11 , DOI: 10.1016/j.kint.2022.07.019
Shruti Gupta , Ian A. Strohbehn , Qiyu Wang , Paul E. Hanna , Rituvanthikaa Seethapathy , Jason M. Prosek , Sandra M. Herrmann , Ala Abudayyeh , A. Bilal Malik , Sebastian Loew , Christopher A. Carlos , Wei-Ting Chang , Pazit Beckerman , Zain Mithani , Chintan V. Shah , Amanda D. Renaghan , Sophie De Seigneux , Luca Campedel , Abhijat Kitchlu , Daniel Sanghoon Shin , Gaia Coppock , Nuttha Lumlertgul , Pablo Garcia , David I. Ortiz-Melo , Arash Rashidi , Ben Sprangers , Vikram Aggarwal , Karolina Benesova , Kenar D. Jhaveri , Frank B. Cortazar , Astrid Weins , Yiqin Zuo , Meghan J. Mooradian , Kerry L. Reynolds , David E. Leaf , Meghan E. Sise